Clik here to view.
Genexine Announces Dosing of First Patient in Phase 2 clinical trial with...
SEOUL, South Korea Genexine (KOSDAQ: 095700), a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of...
View ArticleClik here to view.
Exscientia Business Update for Second Quarter and First Half 2022
OXFORD, England Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005681/en/ Recent developments in the...
View ArticleClik here to view.
Publication in Nature Molecular Psychiatry Supports Genuv’s Alternate Theory...
SEOUL, Republic of Korea Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for central nervous system disorders and advanced antibody therapies for...
View ArticleClik here to view.
European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16,...
INCHEON, South Korea Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the...
View ArticleClik here to view.
Exscientia通报2022年二季度和上半年业务进展
英格兰牛津 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI) 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20220817005682/zh-CN/...
View ArticleClik here to view.
エクセンシアの2022年第2四半期および上半期ビジネスアップデート
英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq: EXAI） 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：https://www.businesswire.com/news/home/20220817005683/ja/...
View ArticleClik here to view.
Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0176...
CRANBURY, N.J. & SHANGHAI Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces that the China National...
View ArticleClik here to view.
InnoCare Releases 2022 Mid-Year Results and Business Highlights
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2022 mid-year results which ended on June 30, 2022. Dr. Jasmine...
View ArticleClik here to view.
Solasia Announces Launch of Darvias® in Japan
TOKYO Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS®...
View ArticleClik here to view.
Pillar Biosciences Receives China National Medical Products Administration...
NATICK, Mass. Pillar Biosciences, the leader in Decision Medicine™, developers and distributors of next-generation sequencing (NGS) tests which localize testing and reduce time to treatment...
View ArticleClik here to view.
Clik here to view.
苏爱康医药宣布在日本推出Darvias®
东京 (美国商业资讯)–苏爱康医药（Solasia Pharma K.K.，TOKYO:4597，总部：日本东京，总裁兼首席执行官：Yoshihiro Arai，以下简称“苏爱康”）今天正式宣布，有机砷药物“135毫克DARVIAS®针剂”（SP-02，以下简称DARVIAS®）已于即日起在日本推出，用于治疗复发或难治外周T细胞淋巴瘤。DARVIAS®将由Nippon Kayaku Co.,...
View ArticleClik here to view.
Quizartinib Marketing Authorization Application Validated by EMA for...
TOKYO & MUNICH Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for quizartinib in combination with...
View ArticleClik here to view.
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and...
View ArticleClik here to view.
Frazier Life Sciences Adds Senior R＆D Leader to Team
MENLO PARK, Calif. Frazier Life Sciences announced the addition of Annette Doherty, Ph.D., OBE, FRSC as a Senior Advisor. She has 35 years of international experience as a chemist and leader of...
View ArticleClik here to view.
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CCR8...
BEIJING InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the Investigational New Drug (IND) of CM369, an anti-CC chemokine receptor 8 (CCR8) monoclonal...
View ArticleClik here to view.
AdvanCell Closes A$18M Series B Funding Led by Morningside
SYDNEY AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18...
View ArticleClik here to view.
AdvanCell完成由晨兴创投领投的1,800万澳元B轮融资
悉尼 (美国商业资讯)–澳大利亚放射性药物公司AdvanCell今天宣布，已完成由晨兴创投领投的1,800万澳元B轮融资。该公司拥有被称为靶向阿尔法疗法(Targeted Alpha Therapy)的革命性癌症治疗平台技术。 AdvanCell创始人兼首席执行官Andrew...
View ArticleClik here to view.
Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2...
BOSTON & HANGZHOU, China Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other...
View ArticleClik here to view.
CANbridge Announces Financial Results and Corporate Updates for Six Months...
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals, Inc. (“CANbridge,” 1228.HK), a China and U.S.-based global biopharmaceutical company committed to the research, development and...
View Article